Introduction
============

Inflammatory bowel disease (IBD) is characterized by an inflammatory process that compromises the digestive tract, partially or totally. Ulcerative colitis (UC) and Crohn's disease (CD) are its main representatives, with distinct and individual pathophysiological, clinical, and pathological characteristics.[@b1-ceg-11-423]--[@b3-ceg-11-423] Although considered uncommon, IBD presents characteristics of chronicity, severity, evolution, and morbidity that significantly affect the quality of life of patients.[@b1-ceg-11-423]--[@b3-ceg-11-423]

Changes in the typical geographic distribution of IBD have been observed over the last years, with increasing rates of incidence and prevalence in regions with low incidence traditionally, such as Asia, South America, and Southern and Eastern Europe; as such, there has been an increase in the consideration of IBD as an emerging global disease.[@b4-ceg-11-423]--[@b6-ceg-11-423] Brazil has been considered as a country with low incidence and prevalence of IBD, although an evident increase in the number of appointments and hospitalizations of patients for IBD has occurred.[@b7-ceg-11-423]--[@b9-ceg-11-423]

There are few Brazilian epidemiological studies, possibly because there is no integrated diagnostic notification system, for IBD. Thus, the aim of this study was to estimate the incidence and prevalence rates of IBD in the State of São Paulo, the most populous in Brazil, between the years of 2012 and 2015, and analyze the patients' demographic characteristics.

Patients and methods
====================

Study design and population
---------------------------

This observational, descriptive, and cross-sectional study included data from 22,638 patients who had initiated their treatment for IBD through the Governmental Program for free supply of high-cost medicines of the Brazilian Unified National Health System (SUS). All the patients registered in the program received salicylates and/or immunosuppressive and/or immunobiological drugs. No patient was excluded from the study.

The Governmental Program for free supply of high-cost medicines of the SUS is responsible for the coverage of \~70% of the population. Data from private health insurance were not included in this study.

The moment of interest of the study was established as the date of initial registration in the Governmental Program of the patient with a diagnosis of CD or UC, with that date being defined as the date of disease onset. The clinical and demographic data, such as age and sex, were collected at that moment. For determining the prevalence, every patient registered in the system was included, regardless of their registration date. For determining the incidence, only patients whose initial registration occurred between January 2012 and December 2015 were included. All information presented herein was extracted from the computerized system of SUS for the State of São Paulo. The International Classification of Diseases codes K50 and K51 were used to identify CD and UC patients, respectively.[@b10-ceg-11-423]

All the data accessed from the SUS is de-identified in order to preserve the privacy and the identity of the studied population.

Quality of the present study was assessed with the Cochrane Collaboration-endorsed Newcastle-Ottawa Quality Assessment Scale (NOS), which was modified to assess aspects of quality relevant to population-based study of incidence.[@b11-ceg-11-423]

Data analyses
-------------

The data collected were initially imported into the DBase III database for processing and tabulation, after which they were exported to spreadsheets in the Microsoft Excel program. Statistical analysis was conducted with analysis of mean and SD, for quantitative analysis, and absolute and percentage frequencies for qualitative variables. The Pearson's chi-squared test (χ^2^) of independence and adherence was used to analyze the qualitative variables and assess if the diseases followed a uniform distribution; mean estimate with a 99% confidence interval (CI 99%). Significance was defined as *P*\<0.01 for all tests.

The incidence and prevalence rates were calculated based on the estimated annual population of the State of São Paulo as follows: 41,939,997 inhabitants in 2012 (20,409,123 males and 21,530,874 females); 42,304,694 inhabitants in 2013 (20,586,963 males and 21,717,731 females); 42,673,386 inhabitants in 2014 (20,766,532 males and 21,906,854 females); and 43,046,555 inhabitants in 2015 (20,948,275 males and 22,098,280 females).

The annual correction of population growth estimated was 0.87%.[@b12-ceg-11-423],[@b13-ceg-11-423]

Ethical approval
----------------

This study was approved by the Research Ethics Committee of the Universidade Estadual Paulista "Júlio de Mesquita Filho" (Protocol Number: 33401214.5.0000.5411).

Results
=======

The study involved epidemiological data of 22,638 individuals out of a total of 43,046,555 patients. CD patients comprised 10,451 (46.16%) and UC patients comprised 12,187 (53.84%) of the selected patients.

Age
---

The mean age of the overall study population was 45.5 (SD ±16.7) years, being 42.66 (SD ±16.2) years for the CD patients and 47.87 (SD ±16.6) years for the UC patients. The distribution of patients according to age is shown in [Figure 1](#f1-ceg-11-423){ref-type="fig"}.

Sex
---

There was a predominance of female sex, corresponding to 59.70% of the overall study population (female:male ratio =1.48:1.00; *P*\<0.0001). The CD patients comprised 6,050 (57.9%) females and 4,401 (42.1%) males (female:male ratio =1.37:1.00; *P*\<0.0001), while the UC patients comprised 7,464 (61.3%) females and 4,723 (38.7%) males (female:male ratio =1.58: 1.00; *P*\<0.0001).

Incidence and prevalence
------------------------

Incidence analyses of IBD cases, as well as CD and UC cases, between 2012 and 2015, are shown in [Figures 2](#f2-ceg-11-423){ref-type="fig"}[](#f3-ceg-11-423){ref-type="fig"}--[4](#f4-ceg-11-423){ref-type="fig"}, respectively. The mean annual incidence of IBD was 13.30 new cases/100,000 inhabitants, considering incidence of CD as 6.14 new cases/100,000 inhabitants/year (mean) and incidence of UC as 7.16 new cases/100,000 inhabitants/year (mean).

The prevalence rates of IBD, both in general and by specific diseases (CD and UC), are shown in [Table 1](#t1-ceg-11-423){ref-type="table"}.

Discussion
==========

Brazil is considered as a country with low incidence and prevalence of IBD.[@b7-ceg-11-423],[@b14-ceg-11-423] Although national databases on incidence and prevalence of these diseases are deficient, there are data that indicate an increasing trend in the occurrence of IBD, even in the absence of precise information on new cases.[@b14-ceg-11-423]

São Paulo State is the most developed state in South America; its near 43 million inhabitants represent 21% of the entire Brazilian population and account for 28.7% of the Brazilian gross national product. About three million immigrants live in the state, coming from more than 70 different nations, and this demographic profile is representative of the overall Brazilian population. In addition, the state utilizes a fully computerized system for its Governmental Program providing the free supply of high-cost medicines, which allows for a safe parameterization of the obtained data.[@b13-ceg-11-423]

The SUS is considered to be one of the largest health systems in the world and was established through the Brazilian Federal Constitution of 1988, since the legislation itself contemplates the right to health for all citizens. The free supply of medication is included in the assistance provided by the SUS.[@b15-ceg-11-423] About 71.1% of the national population uses the system, with \~58% depending exclusively on it. The majority of IBD patients in Brazil obtain their drugs through the Governmental Program for providing the free supply of high-cost medicines, even with the increasing treatment of these patients in the private health system, which has been observed in recent years.[@b15-ceg-11-423],[@b16-ceg-11-423] Data from the private health insurance were not included in this study, which could either overestimate or underestimate the true incidence and prevalence rates. A study performed in Porto Rico showed the IBD prevalence was higher (61.75 cases) among commercial compared to government-sponsored managed health care insured individuals (14.36 cases).[@b17-ceg-11-423]

The slight drop in the incidence rates of CD observed in the study over the years can be explained by the drop in the number of patients enrolled in the Governmental Program in recent years. According to the present study, the incidence of CD was 6.14 new cases/100,000 inhabitants/year (mean) and the incidence of UC was 7.16 new cases/100,000 inhabitants/year (mean). The prevalence rate was 24.3 cases/100,000 inhabitants for CD and 28.3 cases/100,000 inhabitants for UC. The IBD epidemiologic study by Victoria et al published in 2009 and conducted in the Midwestern region of the State of São Paulo demonstrated increases in the incidence between 1986 and 2005 (from 1.0 to 8.0 cases per 100,000 inhabitants) and in the prevalence (from 1.2 to 20.5 cases per 100,000 inhabitants), accounting for 5.6 cases/100,000 inhabitants for CD and 14.8 cases/100,000 inhabitants for UC.[@b7-ceg-11-423] Comparatively, we also observed a significant increase in the rates of incidence of CD and UC between 2012 and 2015. The rate of prevalence of IBD detected in this study, being 52.6 cases/100,000 inhabitants, suggests a growing trend for these diseases in the State of São Paulo.

The numbers determined in the present study are higher than those presented for Brazil in the systematic review by Ng et al, which demonstrated an incidence of CD from 0.81 to 1.94 new cases/100,000 inhabitants/year and an incidence of UC from 1.86 to 3.09 new cases/100,000 inhabitants/year. Concerning the prevalence, our data are also higher to those reported by Ng et al, which varied from 0.6 to 6.75 cases/100,000 inhabitants for CD and from 2.42 to 21 cases/100,000 inhabitants for UC.[@b18-ceg-11-423]

The incidence rate for CD in North America is over 6.38 new cases/100,000 inhabitants/year and for UC is over 7.71 new cases/100,000 inhabitants/year; these are similar to the rates for São Paulo determined in the present study. However, the North American prevalence rates greatly exceed the ones observed in our study, which show over 135.6 cases/100,000 inhabitants for CD and higher than the 198 cases/100,000 inhabitants for UC.[@b18-ceg-11-423]

The results of the present study show incidence rates of IBD in São Paulo comparable to European countries, such as Israel (13.2 new cases/100,000 inhabitants/year), Czech Republic (12.2 new cases/100,000 inhabitants/year), Portugal (11.1 new cases/100,000 inhabitants/year), and Ireland (13.2 new cases/100,000 inhabitants/year). The prevalence of CD was 1.5--213 cases per 100,000 inhabitants and that of UC was 2.4--294 cases per 100,000 inhabitants in these countries.[@b19-ceg-11-423],[@b20-ceg-11-423]

There is little information on IBD epidemiology in Latin America, with data from countries such as Argentina, Uruguay, Puerto Rico, and Mexico referring to the beginning of the 21st century in particular. Those published rates are lower than those found in the present study, with incidence of UC between 2.2 and 4.3 new cases/100,000 inhabitants/year and of CD between 0.8 and 2.0 new cases/100,000 inhabitants/year.[@b21-ceg-11-423],[@b22-ceg-11-423] Despite the low prevalence of IBD in São Paulo, as compared to North America and Europe, the similarity of incidence rates allows us to infer that sometime in the future the prevalence data may equalize, considering the trend toward stabilization or even reduction of the incidence rates of IBD in developed countries that was demonstrated in the systematic review of Ng et al.[@b18-ceg-11-423]

The data of the present study and previous studies related to the epidemiology of IBD in Brazil are demonstrated in [Table 2](#t2-ceg-11-423){ref-type="table"}.

Regarding age, the results of the present study show an evident prevalence of IBD in individuals between 20 and 50 years. In the group of patients with UC, there was a tendency toward an increase in incidence among patients over 60 years old. Such results are indistinct from the ones obtained in other Brazilian studies, such as those by Silva and Souza et al, and international studies, such as those by Burisch and Munkholm and Chouraki et al.[@b8-ceg-11-423],[@b14-ceg-11-423],[@b19-ceg-11-423],[@b23-ceg-11-423] We admit, however, that delay in the diagnosis of IBD can influence the outcome of the incidence distribution by age groups. In a recent study undertaken in the Northeast region of Brazil, a delay of up to 28.2 months was observed between the beginning of the clinical manifestations and the diagnostic confirmation of IBD.[@b24-ceg-11-423]

The results of the present study demonstrated a greater prevalence of IBD among female participants, both for CD and UC. Similar results were observed in studies of other regions of Brazil as well as in Chile, and in the systematic review by Hovde and Moum.[@b1-ceg-11-423],[@b7-ceg-11-423],[@b14-ceg-11-423],[@b25-ceg-11-423],[@b26-ceg-11-423] A recent Brazilian study demonstrated that males seek less health services (63.9%) than females (78%), demonstrating that cultural factors may influence this result.[@b27-ceg-11-423]

The self-reported ethnic group was also evaluated in the study population, with results showing a predominance of the ethnic group self-declared Caucasian (19%), followed by the ethnic group self-declared mixed race (0.3%), African descent (0.1%), oriental descent (0.25%), and indigenous (0.17%), and there was no statistically significant difference between CD and UC patients. These results show ethnic data comparable to those obtained in 2007 from the city of São Paulo, in the POLI study, which demonstrates a predominance of the group self-declared Caucasian (68.9%), followed by the African descent group (7.8%), mixed race (1.5%), oriental descent (1.5%), and indigenous (0.5%).[@b28-ceg-11-423]

In this study, however, 77% of the patients did not declare their ethnic background, making the ethnicity data of the present study only illustrative. The present study is the first in Brazil regarding incidence and prevalence of IBD in a large sample and represents real-life data from a regional population. According to the Cochrane Collaboration-endorsed NOS, our study can be classified as representative of the target population.[@b11-ceg-11-423] Limitations of this study were the non-inclusion of all patients with IBD in Brazil and the lack of other clinical data, such as medications in use, and other data concerning the disease, such as disease extension and presence of complications.

Conclusion
==========

According to the study design and applied methodology, there was a stability in IBD incidence rates and an increase in the IBD prevalence rates in São Paulo state between 2012 and 2015, with a small decrease in CD rates and an increase in UC rates according to SUS data, but with a significant increase in these rates compared to previous studies. The age groups between 20 and 60 years had the highest rates of incidence and prevalence. A higher occurrence was observed in females for both CD and UC. This study also shows that there is much to be explored in relation to the epidemiology of IBD in Brazil, and it is essential for the development of broader surveys that better define the national rates of IBD incidence and prevalence.
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###### 

Prevalence of IBD in the State of São Paulo in December 2015

           CD     UC     Total
  -------- ------ ------ -------
                         
  Male     21.0   22.5   43.5
  Female   27.4   33.8   61.1
  Total    24.3   28.3   52.6

**Note:** Data are presented as new cases per 100,000 inhabitants.

**Abbreviations:** CD, Crohn's disease; IBD, inflammatory bowel disease; UC, ulcerative colitis.

###### 

Data from the present study and from the previous studies related to the IBD epidemiology in Brazil

  Studies                                    CD           UC                       
  ------------------------------------------ ------------ ----------- ------------ -------------
                                                                                   
  Victoria et al (2009)[@b7-ceg-11-423]      3.5          5.65        4.48         14.81
  Molodecky et al (2012)[@b6-ceg-11-423]     1.95--3.76   25.1--48    3.10--4.97   44.4--100.9
  Ng et al (2017)[@b18-ceg-11-423]           0.81--1.94   0.6--6.75   1.86--3.09   2.42--21
  São Paulo State (São Paulo State - 2018)   6.11         24.5        7.13         28.5

**Notes:** Incidence is presented as new cases per 100,000 inhabitants/year. Prevalence is presented as new cases per 100,000 inhabitants.

**Abbreviations:** CD, Crohn's disease; UC, ulcerative colitis.
